March 8, 2022
Mr Clarence Khoo is the Director of Operations and Strategy with the Singapore Translational Cancer Consortium. A clinical pharmacist by training, he is experienced in clinical development, project management and regulatory affairs, having worked in multinational pharmaceutical companies, hospitals and the Singapore regulatory agency. In the roles in the pharmaceutical industry, he has had responsibilities for the planning and operationalisation of regional as well as global clinical studies (early phase to late phase development programmes and non-interventional studies).
SINGAPORE, 7 July 2022 – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company, whose mission is to save and improve lives through early, actionable, and personalized diagnoses with its innovative RNA-powered cancer early detection solutions, announced today the signing of a Memorandum of Understanding (MOU) that launched Project CADENCE (CAncer Detected Early caN be CurEd). Project CADENCE is the world’s first large-scale clinical research project for the discovery and validation of novel combinations blood-borne circulating microRNA (miRNA) and DNA methylation biomarkers that will lead to the development of a multi-cancer early detection test for up to nine high incidence and high mortality cancers, including lung, breast, colorectal, liver, stomach (gastric), esophageal, ovarian, pancreatic, and prostate cancers.
A new national consortium – the Consortium for Clinical Research and Innovation, Singapore (CRIS) – has been officially launched by the Minister for Health Mr Ong Ye Kung on 6 April 2022 CRIS brings together five key national R&D, clinical translation and service initiatives that will advance clinical research and innovation for Singapore, and establish important capabilities for a future-ready healthcare system